{"commentary":{"count":223,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":223},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04566328\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04566328","nct_id":"NCT04566328","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04566328. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION: All patients receive standard induction therapy comprising the following: daratumumab subcutaneously (SC) on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide orally (PO) daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm A (daratumumab, lenalidomide, dexamethasone)","type":"ACTIVE_COMPARATOR"},{"description":"CONSOLIDATION: Patients receive bortezomib SC on days 1, 8, and 15, daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive lenalidomide PO daily on days 1-21 and daratumumab SC on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm B (bortezomib, daratumumab, lenalidomide, dexamethasone)","type":"EXPERIMENTAL"},{"description":"CONSOLIDATION: Patients receive daratumumab SC on day 1, lenalidomide PO daily on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE: Patients receive lenalidomide PO daily on days 1-21, and daratumumab SC on day 1. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm C (daratumumab, lenalidomide, dexamethasone)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma"],"enrollment":{"count":1450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bortezomib","type":"DRUG"},{"name":"Daratumumab and Hyaluronidase-fihj","type":"BIOLOGICAL"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"}],"last_update":"2026-08-19","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Consolidation overall survival","timeFrame":"Time from Step 2 randomization at the start of consolidation to death or to the date last known alive, assessed up to 15 years"}],"references":[],"start_date":{"date":"2021-02-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","url":"https://clinicaltrials.gov/study/NCT04566328"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04566328"}